Abstract. Brain tumors amount to less than 2% of all malignant neoplasms. However, they account for approximately 20% of all childhood cancers and are the leading cause of cancer mortality among children. Recently, enormous progress has been achieved in the field of pediatric neuro-oncology regarding the classification of children's brain tumors, as well as the understanding of the genetic events involved in their pathogenesis; thus leading to an emerging role of molecular diagnostic approaches using novel tools. Comparative genomic hybridization (CGH) is a technique that has revolutionized cytogenetic knowledge in the past decade. It permits the detection of chromosomal copy number changes without the need for cell culturing and gives a global overview of chromosomal gains and losses throughout the whole genome of a tumor. A survey of CGH-related publications on central and peripheral nervous system tumors in the pediatric and adolescent population revealed 884 cases. The CNS tumor groups most frequently examined by CGH were embryonal tumors (268 cases/30.3%) and ependymomas (241/27.2%), followed by astrocytic (163/18.4%), peripheral nerve (73/8.2%), choroid plexus tumors (56/ 6.3%), and craniopharyngiomas (38/4.3%). The most common CNS tumor entities were medulloblastomas (238/26.9%), classic ependymomas (160/18.1%), anaplastic ependymomas (70/7.9%), pleomorphic xanthoastrocytomas (53/6.0%), and pilocytic astrocytomas (50/5.6%). This article provides a short review of the CGH technique and its pitfalls, summarizes the current CGH-related data on pediatric brain tumors and muses on the future of CGH.
HISTORY
Comparative genomic hybridization (CGH) is a technique that has revolutionized cytogenetic knowledge in the past decade. It permits the detection of chromosomal copy number changes without the need for cell culturing and gives a global overview of chromosomal gains and losses throughout the whole genome of a tumor. Thus, CGH is a relatively fast screening technique that can point at specific chromosomal regions that may play a role in the pathogenesis or progression of tumors. Kallioniemi et al were the first to report CGH as a new genetic analysis tool in 1992 (1), followed shortly by du Manoir et al in 1993 (2) .
Initially, it appeared to be rather difficult to perform the technique in less specialized laboratories; however, after the publication of an article reviewing the method in more detail, and after the necessary software was made commercially available, CGH became more accessible to a wider circle (3) . Furthermore, while initially only applicable to fresh and frozen tumor tissue, it soon became possible to use CGH on archival paraffin wax-embedded material. Thus, an increasing number of scientists are using this method nowadays with an equally increasing number of CGH-related investigations regarding research and diagnostic pathology (4) . A review on CGH and its history from 1992 to 1998 revealed the annual number of publications on CGH to have increased from 1 in 1992 to about 100 in 1998 (5) and even further to between 288 and 330 per year in the first 3 years of the new millennium (personal MEDLINE research). Of the 300 or so articles published between 1992 and 1998, approximately 40-and thus the largest group-dealt with CNS tumors followed by technical reports, indicating the need for research in the former field as well as improvement in the latter (5) .
Tumors of the CNS are among the most common childhood neoplasms and a significant cause of neurological morbidity and mortality in the pediatric population. Although brain tumors in general amount to less than 2% of all malignant neoplasms they account for approximately 20% of all childhood cancers, thus making them second in incidence after leukemias, but the most common solid neoplasms in the pediatric population (6) . In most countries, CNS tumors are the leading cause of cancer mortality among children (6) . The earliest articles dealing with CGH-related results among pediatric CNS tumors stem from 1996 and were performed on fibrillary astrocytomas (7) and medulloblastomas (8) . Ever since then, several dozen investigations on hundreds of central and peripheral nervous system neoplasms in children and adolescents have been published. Test/tumor and reference DNA from a healthy donor are differentially labeled (green and red, respectively) and co-hybridized to normal human metaphase chromosomes. The DNA fragments compete for hybridization to their locus of origin on the chromosomes. Fluorescence intensity is measured along the chromosomal axis using digital image analysis and a fluorescence ratio profile is created. Gains of genetic material in the test DNA are seen as an increase in the fluorescence ratio of the tumor at a specific locus (green; peak to the right in the fluorescence ratio profile) and losses as a decrease (red; peak to the left in the fluorescence ratio profile). B: CGH karyogram of an ependymoblastoma of a 2-year-old girl. Note gains over the whole chromosome 2 (ϩ2; increased green fluorescence) as well as loss of material on the long arms of chromosomes 6 and 13 (Ϫ6q and Ϫ13q; red fluorescence). As female tumor DNA was hybridized onto male reference metaphase chromosomes, an alleged gain of X (green) and loss of Y (red) can be seen as internal control for the success of the genetic methods such as loss of heterozygosity (LOH) analysis and classic karyotyping in that it does not involve in vitro culture of tumor tissue or necessitate healthy tissue or blood from a given patient, allows rapid detection and localization of gains and losses across the entire genome, and offers higher resolution than conventional cytogenetics (1) . DNA from archival material can be used, and CGH can be successfully performed using very small amounts of DNA in the order of nanograms. The entire genome is screened for gains and losses of genetic material relative to the ploidy level in a single experiment, and the method is essentially a modified in situ hybridization. Differentially labeled test or tumor (green) and reference (red) DNA from a healthy donor are co-hybridized to normal human metaphases (Fig. 1A) . The DNA fragments compete for hybridization to their locus of origin on the chromosomes. Fluorescence ratios are measured along the chromosomal axis using digital image analysis (Fig. 1B, C) . Gains of genetic material in the test DNA are seen as an increase in the fluorescence ratio of the tumor at a specific locus (ratio Ͼ1.2 or Ͼ1. 25 , depending on laboratory), and losses are seen as a decrease (ratio Ͻ0.8 or Ͻ0.75). In addition to a fluorescence microscope, the technique requires a computer with dedicated image analysis software to perform the evaluation. However, there is a limit to the resolution of this technique: losses are detectable when the region affected exceeds 10 Mb (9, 10), whereas gains are detected if there is a high level amplification of approximately 2 Mb (3, 10, 11). Thus, CGH is far less sensitive than PCR apart from being a relatively time consuming technique. The sensitivity of CGH is also hampered by ''contamination'' of tumor material with normal cells located in the specimen (5). Furthermore, balanced structural rearrangements like balanced translocations, inversions, and ring chromosomes cannot be detected. However, once regions of gain or loss have been established, they can be further delineated by FISH or other molecular genetic techniques, for example, LOH analysis and sequencing in order to identify protooncogenes and tumor suppressor genes (10, 12) .
Several points need to be addressed for a successful CGH analysis, among them high quality metaphase preparations, which should ideally have little cytoplasm in order to counteract high background levels, minimal overlapping of the chromosomes, and low cell density paired with a high mitotic index. The quality of the DNA is also very important: DNA extracted from fresh or frozen tissue is usually of high molecular size and will be of superior quality for labeling purposes. On the other hand, DNA from formalin-fixed and paraffin wax-embedded tissue will be partly cross-linked and degraded into fragments of 300 to 20,000 bp, greatly depending on the pH of the formalin fixative and on the duration of fixation. Thus, neutral buffered formalin (pH 7.0) and fixation for no longer than 24 hours usually result in DNA of sufficient quality. Contamination or dilution of the tumor DNA with normal DNA from stromal or inflammatory cells is also an undesirable but inevitable problem when analyzing tumors; however, if more than 75% of the cells are neoplastic, whole tissue sections can be processed (5) . In cases where the tumor cell content is lower because the neoplasm is diffuse or less cellular, laser-assisted microdissection is advisable in order to avoid copy number changes to become undetectable (13) . Approximately 0.5 to 1 g of DNA is required for 1 CGH experiment, which is generally not a problem when dealing with highly cellular malignant CNS tumors, and optimal fragment length after nick translation should be in the order of 500 to 1,500 bp. Short repetitive DNA sequences occurring throughout the whole genome and varying between individuals have to be blocked with unlabeled Cot-1 DNA. Usually, aliquots of 300 to 350 ng of both tumor and reference labeled DNA are mixed with 100 times the same amount of human Cot-1 DNA, precipitated and resolved in a hybridization mix containing formamide for decreasing the melting temperature of the DNA. After hybridization, the slides are then counterstained with DAPI to produce a banding pattern enabling chromosome identification and karyotyping. Subsequently, a fluorescence microscope is needed for visualization of metaphases for DAPI (blue, chromosome identification), TRITC (red, normal reference DNA), and FITC (green, tumor DNA). Good filter sets combining little crosstalk between the 3 fluorochromes with adequate brightness are a prerequisite and commercially available, usually with an automatic filter wheel to prevent lateral shift during filter changing. The actual image capture and storage time for each slide of 10 to 20 metaphases amounts to approximately 1 hour. Finally, when interpreting the results, chromosomal regions 1p32-pter, 16p, and 19p should be considered with care because of the high amount of repetitive sequences in these areas, which vary between individuals and may produce false positive results. For detailed descriptions of the protocols and techniques, the reader is referred to several excellent reviews on this subject (3, 5, 14, 15) .
SURVEY
A MEDLINE-guided survey of CGH-related publications on central and peripheral nervous system tumors in the pediatric and adolescent population revealed 884 cases of different entities sampled from approximately 50 studies and personal, unpublished data (Table 1) . Where possible, data of individual patients with given age under 18 years were included. However, larger cohorts of brain tumors where the individual patients' ages were not given but dealt mainly with pediatric cohorts or where the tumor entity could generally be regarded as ''pediatric'' (e.g. medulloblastomas or plexus tumors) were also included. On the other hand, entities that generally affect adults rather than children (e.g. oligodendrogliomas or neurocytomas) were intensely scrutinized for patient age and only sampled if the patients were under 18 years of age and CGH data could unequivocally be attributed to an individual pediatric patient. Finally, due to their increased occurrence in the context of the familial tumor syndromes neurofibromatosis type 1 (NF 1) and type 2 (NF2), CGH data on NF-associated peripheral nerve tumors were also included in this survey.
The CNS tumor groups most frequently examined by CGH (Table 2) were embryonal tumors with 268 cases, representing 30.3% of the cohort, and ependymal tumors (241/27.2%). These were followed by astrocytic (163/ 18.4%), peripheral nerve (73/8.2%) and choroid plexus tumors (56/6.3%), as well as craniopharyngiomas (38/ 4.3%) and germ cell tumors (16/1.8%). The most common tumor entities were medulloblastomas (238/26.9%) and classic ependymomas (160/18.1%) followed by anaplastic ependymomas (70/7.9%), pleomorphic xanthoastrocytomas (53/6.0%), and pilocytic astrocytomas (50/ 5.6%) ( Table 3) .
Finally, Table 4 summarizes the most common chromosomal aberrations by giving the number of published studies and cases for each individual histological entity and calculating the relative frequency of a given gain or loss throughout all publications on the given entity, thus homogenizing the data and facilitating interpretation of CGH results.
CGH DATA ON INDIVIDUAL TUMORS
Recently, enormous progress has been achieved in the field of pediatric neuro-oncology regarding the classification of brain tumors, including the introduction of new entities and subtypes (6) , as well as the understanding of the genetic events involved in their pathogenesis, thus leading to an emerging role of molecular diagnostic approaches using novel tools and techniques, one of which is CGH.
The following discussion will focus on the CGH data of each individual histological entity in the order it is listed in the WHO classification of tumors of the nervous system (ref 16 ; Tables 1, 4). As a rule of thumb and with few exceptions, low-grade tumors such as pilocytic astrocytomas, neuronal and mixed neuronal-glial tumors, or pineocytomas tend to show fewer or no chromosomal imbalances compared with high-grade tumors like medulloblastomas and glioblastomas (Tables 1, 4) . Interestingly, 2 WHO grade I tumors showed a rather different pattern: choroid plexus papillomas present with an average of 7 imbalances (17) and myxopapillary ependymomas with 9 imbalances per case (18) , akin to malignant neoplasms such as choroid plexus carcinomas or glioblastomas (17, 19) . Ependymomas also showed a decrease of chromosomal aberrations with increasing malignancy grade so that classic ependymomas present with 5 imbalances and anaplastic ependymomas with less than 2 imbalances per case (18) . Another noteworthy aspect is a bias toward investigating certain tumor groups and entities by CGH (Tables 2, 3 ): in comparison with their relative frequency among pediatric brain tumors, ependymal and embryonal tumors investigated by CGH are heavily overrepresented in contrast to astrocytic neoplasms, for example ( Table 2) . Regarding tumor entities, medulloblastomas and ependymomas in particular have been investigated by CGH, whereas pilocytic astrocytomas (the most common pediatric brain tumors [6] ) and high-grade astrocytic tumors feature below par (Table 3) . Possible reasons for this bias may be, at least from a physician's point of view, a greater interest in medulloblastomas and classic ependymomas because of their more severe clinical impact and a potential value of chromosomal aberrations for therapeutic and prognostic evaluation and decision making. Furthermore, these two are well-circumscribed, highly cellular tumors with little contamination by non-neoplastic cells and thus lend themselves to investigation by CGH, which cannot be said for pilocytic or diffuse astrocytomas.
Astrocytic Tumors
Pilocytic Astrocytomas: Pilocytic astrocytomas typically present in the first 2 decades of life and account for 23.5% of pediatric brain tumors (6; Table 3 ). Two CGH studies on 50 cases showed very few chromosomal imbalances (20, 21 ; Table 1 ). The most common aberration affecting a mere 10% of all tumors consisted of ϩ6q followed by ϩ7q in 8%, whereas the most common loss affected 9q and was found in just 4% of cases (20, 21) . (30) 16p (67) Glioblastoma (n ϭ 28)
13 5 10 1q(54), 3q (38) , 2q, 17q (23) 17, 20q (40) 2q, 4q, 5q, 12q, 13q(40), 8q (30) 6q, 8q, 10q, 13q, 17p (31) 13q, Y (40) 16p ( (33) 1q (20) 1q (30) 1q, 5, 17q, Xp (15) 4q (45) 1q (22), 9p, 18 (17) 4q, 13q, X (33) 22q (25) 10q (30), 22q (20) 16, 17p, 22 (15) 22q (75) (17) X (40) 9p (57) (41) 17p (33) 10q (56), 10p, 22q (47) Choroid plexus carcinoma (n ϭ 16) (47) 22 (100) 22q (73), 5q(40), 5p, 18q (33) 5. Glial tumors of uncertain origin (n (40) 9p (60) 7. Pineal parenchymal tumors (n ϭ 9) (19) 17q (76) 17q (7) 7q, 17q(67), 2p, 2q, 7p(50) 17q(37), 1q (19) 17p (22) 10q, 11(41), 16q, 17p(37), 8p (33) 11 (48) (50) 8p (50) 17p (75) 8, 13q (36) (67) 9p, 11q (50) 3p (75), 5, 6, 14q (50) 4q (50), 9p, 14q, 19q (40) 4q, 12(67), 9, 13, 17p (33) Atypical teratoid/rhabdoid tumor (n ϭ 10) (50) 13q (60) 1p(100), 13q, 17p (44) 1p (67), 11q, 13q, 18q (50) 17p (50) 18q (50) NF1-associated neurofibroma (n Papillary craniopharyngioma (n Langerhans cell histiocytosis (n The last 2 imbalances are noteworthy in that ϩ7q is encountered in other gliomas such as pleomorphic xanthoastrocytomas, ependymomas, and gangliogliomas but also in choroid plexus papillomas, classic medulloblastomas, and PNETs, whereas Ϫ9q is the main aberration in pleomorphic xanthoastrocytomas and is also found in anaplastic astrocytomas and astroblastomas (Tables 1, 4) .
Subependymal Giant Cell Astrocytomas (SEGAs): SEGAs usually arise in the context of tuberous sclerosis complex (TSC), manifest between 2 and 20 years of age, and account for 2.5% of childhood CNS neoplasms (6) . Two CGH investigations of a total of 9 cases failed to record any chromosomal imbalances (20, 22) . Thus, neither of the above studies found any changes regarding the 2 distinct TSC loci on chromosome 9q34 (TSC1) and 16p13.3 (TSC2).
Pleomorphic Xanthoastrocytomas (PXAs): PXAs are mainly encountered in the second decade of life and account for 1.9% of pediatric brain tumors (6) . Two CGH investigations on 53 cases found Ϫ9 to be by far the single most common aberration affecting 49% of specimens, whereas ϩX and Ϫ7 were far rarer with 14% and 11%, respectively (23, 24; Table 1 ). In view of the frequent aberrations among diffuse astrocytomas of the genes encoding p16 and p15-CDKN2A and CDKN2B, respectively-which map to chromosome 9p21, their involvement in the development of PXAs seems feasible. However, a recent molecular genetic analysis of 62 cases failed to show any deletions or mutations of the aforesaid genes; furthermore, other candidate genes (i.e. CDK4, MDM2, and EGFR) were not amplified in any of the cases and only 3 PXAs were shown to carry TP53 mutations, indicating that chromosomal aberrations among PXAs are different than diffuse astrocytomas (25) . One case with multiple genetic alterations showed a poor prognosis (24) .
Fibrillary Astrocytomas: Fibrillary astrocytomas are fairly rare in childhood and make up 5% of CNS tumors encountered in this period (6) . Only 1 CGH study of 8 cases has been performed and showed no chromosomal aberrations in 4 tumors, whereas the other neoplasms presented with no distinct pattern of gains and losses (7; Table 1 ). Loss of 22q (the most frequent aberration among anaplastic astrocytomas) was encountered in 1 tumor.
Anaplastic Astrocytomas: Anaplastic astrocytomas account for 7.2% of childhood brain tumors (6) . To date, 15 specimens have been investigated by CGH (19, 26, 27) . The most common chromosomal aberrations among these anaplastic astrocytomas were ϩ5q (27%) and ϩ1q (20%), as well as Ϫ22q (40%), Ϫ9q (33%), and Ϫ12q (27%) ( Table 1) . Potentially involved protooncogenes mapping to 1q are SKI, PBX1, TRK/TRKC, ABL, ELK4, as well as GAP for 5q, whereas tumor suppressor genes found on 22q include BAM22 and NF2 (19) . Interestingly, 1 study found a significantly shorter survival among (14) 1p, 5, 6, 7, 9, 16, 17, 22q (14) Bold: frequency Ͼ/ϭ 40%. Bold and underlined: frequency Ͼ/ϭ 60%.
patients with anaplastic astrocytomas showing ϩ1q (19) , an association that has also been reported for ependymomas, which when shown to harbor ϩ1q, tended to occur in the posterior fossa of children and behave aggressively (28, 29) . Glioblastomas: Glioblastomas account for 7.2% of childhood brain tumors (6) . So far, 28 specimens have been investigated by CGH (19, 27, 30) , of which 5 were examined after radio-chemotherapy (30) . Similar to anaplastic astrocytomas, the most common chromosomal aberrations were ϩ1q and ϩ2q (25% each), ϩ3q and ϩ17q (18% each), as well as Ϫ17p (29%) and Ϫ13q (21%). Potentially involved protooncogenes mapping to 1q are SKI, PBX1, TRK/TRKC, ABL, ELK4, and LAZ3/ MLF1 for 3q, whereas 17p contains tumor suppressor genes TP53 and OVCA1/2 and chromosome 13q the retinoblastoma gene RB1 (19) . Compared with adult cases, gains of 1p, 2q and 21q as well as losses of 6q, 11q and 16q were more frequently observed among pediatric malignant astrocytomas, showing that chromosomal aberrations not only differ between childhood anaplastic astrocytomas and glioblastomas but also between pediatric and adult high-grade astrocytomas, supporting the notion of different genetic pathways (19) .
Oligodendroglial Tumors
Oligodendroglial tumors are exceedingly rare in the pediatric population and so far, only 1 CGH study has been performed showing no chromosomal imbalances in 1 oligodendroglioma WHO grade II, whereas 2 anaplastic oligodendrogliomas exhibited aberrations without a distinct pattern (20) .
Ependymal Tumors
Ependymomas make up the second largest tumor group investigated by CGH, containing 262 samples from 20 publications (Tables 1-4 ) and comprising 10.1% of children's brain tumors (6) . All 3 subentities and tumor grades of ependymomas have been investigated. Interestingly, 1 study found that there were little or no chromosomal imbalances in anaplastic ependymomas, whereas most classic and myxopapillary ependymomas exhibited numerous gains and losses (2, 5.5, and 9, respectively), indicating that in contrast to other brain tumors, genomic imbalances revealed by CGH are not an indicator of high WHO grade among ependymomas (18) . Furthermore, there is now increasing evidence that spinal and intracranial ependymomas represent 2 different subsets of tumors and that their clinical behavior is related to their respective cytogenetic profiles (28, 31) . Comparing the CGH data of the respective subgroups, classic and anaplastic ependymomas are characterized by ϩ1q, whereas all 3 entities (including the myxopapillary variant) frequently show ϩ9 (Table 4 ). Regarding DNA deletions, the 3 groups offer quite distinct patterns in that myxopapillary ependymomas most commonly present with Ϫ13q, classic ependymomas with Ϫ22q, and anaplastic ependymomas with Ϫ9 (Table 4) . Thus, cytogenetic analysis of ependymal tumors may help classify them and provide leads concerning their initiation and progression. Furthermore, cytogenetic aberrations differ between younger and older patients, thus pointing toward potentially age-related differences in outcome (31) . Additionally, when comparing the CGH data of the 2 large glioma groups, namely astrocytic and ependymal tumors, both show a predominance for ϩ1q, ϩ7q, and ϩ9 as well as for Ϫ9 and Ϫ22q, with ϩ9 being more common in ependymomas and Ϫ9 in astrocytic neoplasms (Tables 1,  4) .
Myxopapillary Ependymomas: So far, 4 CGH studies on 11 pediatric myxopapillary ependymomas have been published (18, 28, 31, 32 ; Tables 1, 4 ). Overall, gains were far more common than losses (in contrast to classic ependymomas) and mainly affected 7 (82%), 9q (73%), 18 (64%), and 9p (55%), whereas the most common losses were on 2q and 6q (45% each) and 2p and 13q (36% each). Gains of chromosomes 7 and 9 are also frequently encountered among low-grade astrocytic tumors (Tables  1, 4) .
Gains of 9q were almost exclusively detected among myxopapillary ependymomas where they occurred in 73% of tumors compared with 6% and 10% among classic and anaplastic ependymomas, respectively ( Table 4) . The terminal region of this chromosome includes the oncogene ABL1 (9q34.1); however, FISH-analysis did not show any high-level amplification (18) . Gains of 1q, which are often involved in higher-grade ependymomas, do not play a role among myxopapillary ependymomas (Tables 1, 4 ). Loss of 13q is one of the most common deletions and contains the RB1 gene locus; however, RB1 protein expression was found to be unremarkable (18) . Another CGH study claimed that in contrast to highergrade ependymomas, Ϫ22q, ϩ12, and ϩ15q were not encountered in myxopapillary ependymomas. Moreover, among spinal tumors, Ϫ1 and Ϫ10 were associated with a younger patient age of less than 10 years (31).
Classic Ependymomas: Classic ependymomas account for 3.8% of all childhood brain tumors (6). So far, 11 CGH studies on 160 ependymomas WHO grade II have been published (Tables 1, 4) . Overall, losses were more common than gains (in contrast to the myxopapillary variant) and consisted of Ϫ22q (31%), Ϫ10q (12%), and Ϫ6p (10%), whereas the most common gain was on 1q with 16% (Table 4) . Gains of 1q were selectively found in childhood ependymomas grade II and III (18, 32) , whereas ϩ9q was almost exclusively detected in the 2 groups of lower-grade ependymomas (18) . Thus, ependymomas show similarities in their DNA copy number changes to other gliomas (Tables 1, 4) . One CGH study comparing 14 spinal and 10 intracranial grade II ependymomas found the most frequent aberrations in intracranial ependymomas to be ϩ1q and Ϫ6q, Ϫ9 and Ϫ13, whereas ϩ7 was almost exclusively encountered in spinal ependymomas where it was often associated with Ϫ22 (31). This is corroborated by Carter et al who found Ϫ22 to be the most common aberration in 24% of cases and significantly associated with spinal location (28) . Interestingly, Ϫ6q overwhelmingly affected infratentorial tumors (28, 31) . Equally, classic ependymomas with ϩ1q tended to occur in the posterior fossa of children and were characterized by an aggressive clinical course as found among anaplastic ependymomas (28, 29) . Furthermore, ϩ1q was not only associated with a poorer outcome but also strongly linked with tumor recurrence (29) . Ependymomas with Ϫ9p were all infratentorial tumors and the patients under 3 years of age; in contrast, Ϫ9q was significantly correlated with histological grade WHO III and supratentorial location (31) . The number of chromosomal imbalances was greater for spinal than intracranial cases and preferentially covered whole chromosome arms. Thus, intracranial and spinal cord ependymomas seem to progress along substantially different pathways although they comprise 1 histological entity. Additionally, all children diagnosed at an age younger than 3 years showed a balanced genetic profile, conversely, 86% of children diagnosed at an age older than 3 years showed either structural or numerical genetic aberrations (31) . Overall, between 39% and 43.9% of pediatric ependymomas showed a balanced, i.e. normal CGH profile, while this was true for less than 10% of adult cases (28, 31, 32) . This strongly suggests that ependymomas occurring in infants are biologically distinct from those in older children and adults (29) . Additionally, Carter et al found a balanced chromosomal profile in 32% of intracranial but only 3% of spinal ependymomas (28) , similar to the 21% and 0% encountered by Hirose et al (31) , further indicating that intracranial and spinal tumors differ in their genetic profiles and that the development of pediatric ependymomas is often independent of chromosomal instability (29, 33 ).
An extensive CGH study of ependymomas from adult and pediatric patients showed an overlap in chromosomal aberrations between the 2 age groups; however, in agreement with the study by Hirose et al, posterior fossa ependymomas showed Ϫ6 and ϩ9 while supratentorial ependymomas were characterized by Ϫ9 (34). Furthermore, infratentorial cases often presented with Ϫ22 (34). The largest study (consisting of 40 ependymomas) frequently showed ϩ1q (20%) and Ϫ22q (25%), without an association of aberrations with benign versus anaplastic histology (35) . However, ϩ7q and ϩ9p as well as Ϫ17 and Ϫ22 were significantly more common in recurrent compared with primary ependymomas (35) . Finally, 1 study found classic ependymomas with 6 or less chromosomal imbalances (termed ''structural'' tumors by the authors) to be associated with a significantly worse outcome compared with balanced and so-called ''numerical'' tumors with 13 or more aberrations per case (29) .
Except for an association of Ϫ22q with the NF2 gene in the setting of spinal (not intracranial) ependymomas arising in this familial tumor syndrome (36) , no candidate tumor suppressor or oncogenes have been put forward for ependymoma tumorigenesis (37) , and involvement of the hSNF5/INI-1 gene has been ruled out (38) . However, a recent publication on gene expression patterns in ependymomas found high levels of HOXB5, PLA2G, and CDKN2A among spinal ependymomas as well as LDHB and STAM in tumors of patients under 16 years of age. Moreover, the same study showed that supratentorial ependymomas of WHO grade II and III could be distinguished with 100% accuracy by means of signature genes relevant to cell cycle control, signal transduction, and invasiveness (33) . Increased expression was also found for PRELP, EPHX1, FY, and HSPA6, all located on chromosome arm 1q (33) .
Anaplastic Ependymomas: Anaplastic ependymomas account for 6.3% of all childhood brain tumors (6) . So far, 5 CGH studies on 70 anaplastic ependymomas WHO grade III have been published (Tables 1, 4 ). In all of these investigations ϩ1q was the most commonly found imbalance encountered in between 22% (18) and 42% (29) of cases (Table 1) . Overall, ϩ1q was the most common aberration among anaplastic ependymomas with an incidence of 30% (Table 4 ). Similar to classic ependymomas, anaplastic ependymomas with ϩ1q also tend to occur in the posterior fossa of children and behave aggressively (28, 29) . Both studies found a significantly worse outcome and survival for anaplastic ependymomas with ϩ1q compared with anaplastic ependymomas without ϩ1q and classic ependymomas (28, 29) , an observation also made among pediatric anaplastic astrocytomas (19) . However, in anaplastic ependymomas, ϩ1q was not only associated with a poorer outcome but was also strongly linked with tumor recurrence. This adverse effect of ϩ1q on survival has previously also been shown for neuroblastomas, Wilm's tumors, and Ewing's sarcomas (29) . Moreover, anaplastic ependymomas were preferentially associated not only with ϩ1q but also with Ϫ9 (31). However, overall gains and losses of 9 occurred in similar frequencies (Table 4) . Finally, 1 study found anaplastic ependymomas with 6 or less chromosomal changes to be associated with worse outcome compared with balanced cases and such with 13 or more aberrations (29) .
Choroid Plexus Tumors
Choroid plexus tumors occur most often in childhood where they constitute 0.9% of CNS neoplasms (6) . So far, 2 CGH studies have been undertaken on 56 specimens consisting of 34 papillomas and 15 carcinomas in 1 investigation (17) and 6 papillomas and 1 carcinoma in the other (39) . The larger study found that choroid plexus papillomas frequently showed gains of 7q (65%), 5q (62%), 7p (59%), 5p (56%), 9p (50%), 9q (41%), 12 (38%), and 8q (35%), as well as losses of 10q (56%), 10p, and 22q (47%). Choroid plexus carcinomas revealed gains of 12, 20p (60%), 1, 4q, 20q (53%), 4p (47%), 8q, 14q (40%), 7q, 9p, and 21 (33%), as well as losses of 22q (73%), 5q (40%), 5p, and 18q (33%) (17; Table 1 ). Several chromosomal imbalances were characteristic for a tumor entity or age group. In papillomas, gains of 5q, 6q, 7q, 9q, 15q, and 18q as well as losses of 21q were significantly more common, whereas carcinomas were characterized by gains of 1, 4q, 10, 14q, 20q, and 21q, and losses of 5q, 9p, 11, 15q, and 18q. Among plexus papillomas, children more often showed gains of 8q, 14q, 12 and 20q. In contrast, adults mainly presented with gains of 5q, 6q, 15q, and 18q and losses of 22q. Although the number of overall aberrations as well as gains and losses bore no significance on survival among choroid plexus tumors, a significantly longer survival among patients with plexus carcinomas was associated with ϩ9p or Ϫ10q (17). The smaller cohort underscored some of the above data by 3/6 papillomas showing ϩ7 and the only carcinoma revealing Ϫ22 (39).
Presently, no convincing evidence in favor of a particular gene involved in the tumorigenesis of choroid plexus tumors has been put forward (17) . However, Ϫ22q in a high proportion of cases corresponds with the finding of hSNF5/INI-1 inactivation among choroid plexus neoplasms (38) and the occurrence of plexus carcinomas in the setting of rhabdoid predisposition syndrome caused by germ line inactivation of the INI-1 gene (40) . LOH of chromosome 22q11 secondary to a hSNF5/INI1 germ line mutation was found in 1 family with plexus carcinomas and 1 sporadic carcinoma. The occasional development of choroid plexus neoplasms in hereditary tumor syndromes, such as Down's, neurofibromatosis type 2, and von Hippel-Lindau disease, may point toward an involvement of chromosome 21 as well as the NF2 and VHL tumor suppressor genes on 22q12 and 3p25-26, respectively (17) .
Glial Tumors of Uncertain Origin
Astroblastomas: Astroblastomas are rare glial neoplasms with preferential manifestation in young adults and occasionally in children. So far, 10 cases have been investigated by CGH of which 7 have been published (41) . These showed ϩ20q (57%) and ϩ19 (42%) as well as Ϫ9q, Ϫ10, and ϪX (28%). Therefore, although astroblastomas present histological features akin to ependymomas and astrocytomas, they show different chromosomal changes from them (41) . CGH results on 3 astroblastomas in the authors' series yielded no chromosomal imbalances (unpublished data).
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Neuronal and Mixed Neuronal-Glial Tumors
Dysplastic Gangliocytomas of Cerebellum (LhermitteDuclos):
No CGH data has yet been published on this entity.
Gangliocytomas: No CGH data has yet been published on this entity.
Desmoplastic Infantile Astrocytomas/Gangliogliomas (DIA/Gs): DIA/Gs are large cystic neoplasms of infancy. Their age range is 1 to 24 months and they account for 0.6% of pediatric brain tumors (6) . So far, 3 cases have been assessed by CGH that showed only 2 chromosomal imbalances consisting of Ϫ8p22-pter and ϩ13q21 in 1 case each (42) . These low-grade lesions show little genetic instability and the few genetic aberrations found in these cases differ from those encountered in common astrocytomas.
Dysembryoplastic Neuroectodermal Tumors (DNTs): DNTs are benign glio-neuronal neoplasms of child-and young adulthood and account for 0.6% of pediatric brain tumors (6) . So far, only 2 cases have been investigated by CGH, which, interestingly, happened to stem from father and daughter who had been operated on at the ages of 5 and 6 years, respectively. Neither tumor showed any imbalances (43; Table 1) .
Gangliogliomas: Gangliogliomas are well differentiated, slow growing tumors composed of neoplastic mature ganglion cells in combination with neoplastic glial cells. So far, 5 cases have been investigated by CGH, of which 2 showed ϩ7q and three Ϫ9p (44). Whereas ϩ7 is a frequent event in astrocytic neoplasms, Ϫ9p is closely associated with transition of low-grade to anaplastic astrocytoma or glioblastoma.
Pineal Parenchymal Tumors
Pineal parenchymal tumors (PPTs) are rare neoplasms derived from pineocytes or their embryonal precursors and span a wide spectrum of differentiation that is paralleled by differences in biological behavior, clinical outcome, and molecular genetics. They account for 1.9% of pediatric brain tumors (6) . As yet, only 1 publication has dealt with the application of CGH on 9 cases consisting of 3 specimens each of pineocytoma, pineoblastoma, and pineal parenchymal tumor of intermediate differentiation (PPTID) (45) . No chromosomal changes per pineocytoma, 5.3 per PPTID and 5.6 per pineoblastoma were found. The most frequent DNA copy number changes among PPTID and pineoblastomas were gains of 12q (50%), 4q, 5p, and 5q (33% each) and losses of 22 (67%), 9q, and 16q (33% each) ( Table 1) . Among PPTIDs, the most common imbalances were ϩ4q and ϩ12q as well as Ϫ22 (67% each), the latter of which was also prominent in pineoblastomas (67%). In accordance with previous cytogenetic results, Ϫ22 seems to play a role in PPT while other reported changes, such as ϩ17q or Ϫ11 and Ϫ12q, were not found in any of the tumors in this series. In contrast, gains of 12q were found in 3 of the 6 higher-grade PPTs. Moreover, regarding alterations in the MYC and TP53 gene regions, only one ϩ8q and no Ϫ17p were encountered; however, in view of the role of the retinoblastoma gene RB1 mapping to 13q14 in the familial trilateral retinoblastoma syndrome, it is intriguing to speculate about its involvement in 1 of the 3 pineoblastomas showing Ϫ13q. Thus, PPTIDs are cytogenetically more similar to pineoblastomas. Furthermore, imbalances in higher-grade PPT mainly affect ϩ12q and Ϫ22 (45).
Embryonal Tumors
Embryonal tumors make up the largest group investigated by CGH, consisting of 268 samples from 30 publications (Tables 1-4 ) and accounting for 19.5% of brain tumors in children, thus being the most common malignant pediatric CNS neoplasms (6) . Of these, medulloblastomas have been most extensively investigated by CGH (238 cases) followed by PNETs (19 cases) and AT/ RT (10 cases; Tables 1, 4) .
Medulloblastomas: Medulloblastomas are the single most frequently CGH-investigated tumor entity and account for a quarter of all neoplasms in this survey (Table  3) . Most data concern classic medulloblastomas; however, several CGH studies examined 21 cases each of the desmoplastic and large cell/anaplastic varieties (Tables 1,  4) .
Among classic medulloblastomas, ϩ17q was the single most common aberration and was encountered in between 45% and 61% of cases (Table 4) , a change also found in high-grade neuroblastomas (46) . Ϫ17p, on the other hand, was the single most common loss, reiterating the well-known fact that it is a specific abnormality of medulloblastomas, usually through the formation of an isochromosome 17q [i(17q)] (47). The combination of ϩ17q/Ϫ17p is also the most common imbalance among large cell/anaplastic medulloblastomas, occurring in 62% and 33% of cases, respectively (Table 4) . Additionally, ϩ7, often seen in tumors with i(17q), was the second most common cytogenetic abnormality among classic and desmoplastic lesions. This combination is also frequently found in carcinomas of the breast, kidney, lung, uterus, ovary, and oral cavity (48) . Although the TP53 gene is located on chromosome 17p, it is infrequently mutated in medulloblastomas, suggesting that as yet unknown and more distally located genes may be the target of Ϫ17p (48) . A completely different CGH profile pattern emerges among desmoplastic medulloblastomas, which not only show far fewer DNA copy number changes compared with the other 2 subgroups but are characterized by Ϫ9q, which was found in a quarter of the cases, whereas ϩ17q only occurred in 10% (Table 4) gene is mutated in sporadic and familial medulloblastomas, the latter in the setting of Gorlin's or nevoid basal cell carcinoma syndrome. Moreover, 1 comparative study of 17 classic and 14 desmoplastic medulloblastomas found a significantly worse outcome for classic cases with Ϫ22, which also tended to occur in young patients with a median age of 8 months (49) . Substantial Ϫ22 was found in 1 other study, affecting 12% of cases (50) . These findings raise the question of a relationship between these cases with AT/RT. Interestingly, the same study revealed that cases with ϩ7 or ϩ7q also showed Ϫ8, while 80% of medulloblastomas with Ϫ8p additionally showed ϩ17q (49). Gain of 17q did not convey any influence on survival; however, amplifications of NMYC or LMYC seemed to indicate poor clinical outcome (51). In 3 studies, substantial ϩ12q was encountered in 16% to 20% of cases (49, 52, 53) , pointing toward a potential involvement of the EGFR pathway substrate 8 (49) . Equally, Ϫ10q (found in 18% to 42% of cases in 4 studies) may involve tumor suppressor genes DMBT and PTEN (20, 46, 52, 54) . Moreover, occasional cases presented with ϩ2p and ϩ8q, which were found to contain amplifications of the protooncogenes MYCN and MYCC, respectively (8, 48, 53, 54) . Interestingly, in 1 series, none of the patients with amplifications of MYC genes responded to therapy (8) .
Another recent comparative investigation of 5 desmoplastic, 10 classic, and 18 large cell/anaplastic medulloblastomas also revealed that the desmoplastic variant is characterized by rather distinct aberrations not found among the other two, e.g. ϩ4q and ϩ13q (53; Tables 1,  4) . Apart from presenting with the most aberrations per case and the most high-level gains, 50% of large cell/ anaplastic medulloblastomas also showed either CMYC or NMYC amplification, with Ϫ17p only found among large cell/anaplastic cases. This study supports an association between myc oncogene amplification, 17p loss, and large cell/anaplastic histology, and underscores reports that LOH of 17p is associated with poor clinical outcome (53) .
PNETs: Supratentorial primitive neuroectodermal tumors are rare embryonal neoplasms and account for just 1.9% of pediatric brain neoplams (6) . CGH data on 19 cases have been presented by 4 groups (46, (48) (49) (50) . Whereas losses mainly affected chromosomes 4q, 9p, and 14q in 32% and 19q in 21% of cases (aberrations not found among infratentorial medulloblastomas), the most common gain was ϩ7 (26%), potentially involving the EGFR protooncogene on 7p, as well as ϩ1q and ϩ8q (21%) (Tables 1, 4) . Although ϩ7 was also frequently encountered among medulloblastomas, ϩ8q was only found in the large cell/anaplastic variety; ϩ1q did not feature in medulloblastomas but was encountered in 1 of 10 AT/RTs (55; Tables 1, 4) . Moreover, a comparative study of 43 medulloblastomas and 10 PNETs found statistically significant differences in copy number aberrations for chromosomes 14 (Ϫ14 in 40% of PNETs but 0% of medulloblastomas), 17 (ϩ17 in 0% of PNETs but 37% of medulloblastomas), and 19 (Ϫ19q in 40% of PNETs but only 2% of medulloblastomas) (50). Consequently, i(17q), which is frequently involved in medulloblastomas, does not seem to play a role among PNETs.
Atypical Teratoid/Rhabdoid Tumors (AT/RTs): AT/RTs account for 1.3% of pediatric brain tumors (6) and manifest in children, of whom 94% are under 5 years of age (55) . To date, 2 CGH studies on a total of 10 AT/RTs have been published showing Ϫ22q in 90% of cases and Ϫ19p in 50% (56) and either no gains (56) or no distinct pattern of gains (55; Table 1 ). In particular, Ϫ22q is worth mentioning as hSNF5/INI1 (the gene thought to be involved in AT/RTs) maps to chromosome band 22q11.2 (38) . The product of this gene is involved in chromatin remodeling and heterozygous hSNF5 knockout mice develop tumors of the CNS with a rhabdoid phenotype (55) . Similar chromosomal changes with Ϫ22q have been found by CGH in a high number of choroid plexus tumors, among which 46% of papillomas and 73% of carcinomas showed that particular aberration (17) . This corresponds with the finding of hSNF5/INI-1 inactivation among plexus tumors (38) and the occurrence of choroid plexus carcinomas in the setting of rhabdoid predisposition syndrome caused by germ line inactivation of the INI-1 gene (40). In addition to the 2 major aberrations of Ϫ22q and Ϫ19, one case showed additional losses of 16p, 17p, and 20q (56) . Loss of 8p, as found in another case, is also encountered in medulloblastomas (55) .
Medulloepitheliomas: No CGH data has yet been published on this entity.
Ependymoblastomas: Ependymoblastomas are rare tumors of neonates and young children. No CGH data has been published yet; however, 1 case investigated by the authors showed ϩ2 as well as Ϫ6q and Ϫ13q (unpublished data; Fig. 1B, C) . The latter aberration is frequently encountered in AT/RTs, ependymal and choroid plexus tumors, as well as neoplasms of the peripheral nervous system (Table 4) .
Medullomyoblastomas: No CGH data has yet been published on this entity.
Tumors of the Peripheral Nerves
Although mainly affecting adolescents or young adults rather than children, these tumors have been included in this survey because of their association with the familial genetic tumor syndromes neurofibromatosis type 1 (NF1, von Recklinghausen disease) and type 2 (NF2), in the context of which these neoplasms tend to occur at a younger age. These syndromes are autosomal dominant disorders, in the setting of NF characterized by multiple neurofibromas, malignant peripheral nerve sheath tumors (MPNST) and optic nerve gliomas (57) , in NF2 with bilateral vestibular schwannomas as the hallmark (58) . The chromosomal locus is on 17q12 for NF1 (57) and on 22q12 for NF2 (58) .
NF1-Associated Malignant Peripheral Nerve Sheath Tumors (MPNSTs):
Five CGH studies on 40 NF1-associated MPNSTs have been published (57, 59-62; Table  1) . Surprisingly, these cases showed gains rather than losses of 17q as the most frequent aberration (63% of cases) encompassing the NF1 locus. ϩ7q and ϩ8q were also encountered in about half the cases, whereas losses were infrequent but also affected Ϫ13q and Ϫ17p, regions of the RB1 retinoblastoma and TP53 tumor suppressor genes, respectively (Tables 1, 4 ). Gains on 8q may point toward an involvement of the MYC oncogene located on 8q24. However, 1 investigation found no CMYC gene amplification or loss of the TP53 gene by locus-specific probes (63) . In another survey, all NF-associated but only 75% of sporadic nerve sheath tumors showed chromosomal imbalances (62) . Furthermore, whereas in MPNSTs from patients with von Recklinghausen's disease, gains of 7q, 8q, 15q, and 17q predominated, sporadic cases were characterized by gains of 5p, 6, 8q, and 20q (61) . However, no such differences were observed by Mechtersheimer et al (60) . One study found the occurrence of ϩ7p and ϩ17q to be associated with a significantly poorer overall survival rate (61) .
NF1-Associated Neurofibromas: So far, 2 CGH studies on 21 NF1-associated neurofibromas have been published (57, 62; Table 1 ). Whereas the smaller cohort did not show a distinct aberration pattern (57) , the other investigation featuring 15 cases showed frequent gains of 4q (60%), 5q, 13q, (53%) and 8q (40%) as well as losses of 17p, 19p, 22q, (60%) and 19q (53%); thus presenting with similar chromosomal imbalances to MPNSTs (62) . Interestingly, ϩ17q was more frequently encountered among NF1-associated plexiform neurofibromas whereas non-plexiform neurofibromas were characterized by Ϫ17q, underscoring the well-known fact that plexiform neurofibromas in the setting of NF1 are prone to malignant transformation into MPNSTs which also show a high number of ϩ17q (62) . Furthermore, 17q status may be useful for differential diagnosis of benign and borderline lesions.
NF2-Associated Neurinomas:
A CGH study on 12 NF2-associated and 13 sporadic neurinomas found the number and type of aberrations to be similar between the 2 subgroups (58). Ϫ22q was by far the most common aberration and more frequently encountered in NF2-associated cases (42%) compared with sporadic neurinomas (23%). This corresponds with the chromosomal locus for NF2 on 22q12.
Melanocytic Lesions
Diffuse Melanocytosis: No CGH data has yet been published on this entity.
Germ Cell Tumors (GCTs)
GCTs of the CNS constitute a unique class of rare neoplasms that mainly affect children and adolescents. They account for 2.5% of pediatric brain tumors in the West but are far more prevalent in Asia, for example, 4% to 12% in Japan (6, 64) . So far, CGH data from 16 cerebral GCTs (one of them a fetal immature teratoma [65] ) have been published (64; Table 1 ). One study investigated 8 germinomas, 4 mixed teratomas-germinomas, 2 immature teratomas, and 1 yolk sac tumor with 2 recurrences (64). The most frequent imbalances overall were ϩ12p (40%), ϩ8q (27%), and ϩ1q (20%) as well as Ϫ13q (47%), Ϫ18q (33%), Ϫ9q, and Ϫ11q (20% each). Among germinomas, the most common aberrations were Ϫ13q and Ϫ18q (38% each), in mixed teratomas-germinomas ϩ8q (100%) and ϩ12p (75%) as well as Ϫ13q (75%) and Ϫ9q (50%). Additionally, the primary yolk sac tumor showed 2 imbalances whereas the first recurrence showed 7 and the second showed 13 changes (64). Thus, aberrations in cerebral GCTs affect the same chromosomes as in their extracranial counterparts, albeit in a considerably lower frequency among cerebral germinomas where ϩ12p does not seem to play a major role. Presently, no convincing evidence in favor of a particular gene involved in GCT tumorigenesis has been put forward (64) . Molecular analysis of intracranial GCT has so far been limited to investigations of the TP53 tumor suppressor and MDM2 gene. In these cases, mutations of TP53 were detected in 1 of 7 germinomas and 3 of 5 yolk sac tumors as well as in 1 immature teratoma out of 16 GCTs (reviewed in 64). Another study failed to demonstrate any TP53 mutations in 7 germinomas, 5 teratomas, and 2 embryonal carcinomas. MDM2 gene amplifications, on the other hand, were detected in 3 germinomas out of 16 GCTs, which also showed p53 and mdm2 protein overexpression in most cases (reviewed in 64).
Craniopharyngiomas
Craniopharyngiomas are the most common non-neuroepithelial intracranial neoplasms in children and account for 5.6% of pediatric brain tumors (6) . Although no chromosomal aberrations were found in 20 adamantinomatous and 9 papillary craniopharyngiomas in one study (66) , another study presented gains of 1p, 9q, 12q, 17, 19, 20q, 22q, X, and Yq in one third of 9 adamantinomatous craniopharyngiomas (67; Table 1 ).
Tumors of the Hematopoietic System
Langerhans Cell Histiocytosis: Langerhans cell histiocytosis typically occurs in children with a mean of 12 years, usually presents as a solitary osteolytic lesion of the skull and accounts for 0.6% of pediatric brain tumors (6) . So far, only 1 CGH investigation has been done on
